EUVIMEDOpdag EUVIMED
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen access · CC BY-NC 4.0

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

Andrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska iD, Raul De Lucas Laguna, Michael Ziv, Shoba Ravichandran, Amita Bansal, Swapnil S Dahale, Ruvie Martin, Bertrand Paguet, Nina Magnolo iD, Kulli Kingo

Journal of the European Academy of Dermatology and Venereology · 2026

DOI: 10.1111/jdv.70155 ↗

At a glance

Klinische Studie (Phase III) in Journal of the European Academy of Dermatology and Venereology, 2026. Written by Andrzej Kaszuba and 11 co-authors. Institution: DERMED Medical Services, Lodz, Poland. Major MEDLINE topics: Psoriasis, Antibodies, Monoclonal, Dermatologic Agents. Cited 4 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Novartis Pharma AG, Basel, Switzerland.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population. In a Phase 3 study ( NCT02471144 ), secukinumab treatment for up to 104 weeks demonstrated good tolerability and efficacy in paediatric patients with severe chronic plaque psoriasis.

Objectives

Final long‐term safety and efficacy results of secukinumab through 236 weeks of treatment in paediatric patients with severe chronic plaque psoriasis.

Methods

During the extension period (Weeks 52–236), paediatric patients aged 6 to

Subjects

MeSH terms (MEDLINE)

PsoriasisAntibodies, MonoclonalDermatologic AgentsHumansAntibodies, Monoclonal, HumanizedChildAdolescentMaleFemaleSeverity of Illness IndexTreatment OutcomeDouble-Blind Method

Author keywords

CDLQIIGAPASIpaediatric psoriasispsoriasissecukinumab

Substances

secukinumabAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalDermatologic Agents

Authors and institutions

  • DERMED Medical Services, Lodz, Poland.
  • Novartis Pharma AG, Basel, Switzerland.
  • Department of Dermatology, Venerology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland.
  • Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain.
  • Department of Dermatology, Emek Medical Center, Afula, Israel.
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

ORCID profiles: Dorota Krasowska, Nina Magnolo

Funding

  • Novartis Pharma AG, Basel, Switzerland

Cite

APA

Kaszuba, A., Papanastasiou, P., Krasowska, D., De Lucas Laguna, R., Ziv, M., Ravichandran, S., Bansal, A., Dahale, S. S., Martin, R., Paguet, B., Magnolo, N., & Kingo, K. (2026). Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70155

Vancouver

Kaszuba A, Papanastasiou P, Krasowska D, De Lucas Laguna R, Ziv M, Ravichandran S, et al. Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70155

BibTeX
@article{Kaszuba2026,
  author = {Kaszuba, Andrzej and Papanastasiou, Philemon and Krasowska, Dorota and De Lucas Laguna, Raul and Ziv, Michael and Ravichandran, Shoba and Bansal, Amita and Dahale, Swapnil S and Martin, Ruvie and Paguet, Bertrand and Magnolo, Nina and Kingo, Kulli},
  title = {Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70155}
}
Start for free →